Focused Issue on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions

Posted On 2019-10-29 01:45:12


This focused issue on "Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions" is edited by Drs. Silvia Novello and Francesco Passiglia.

Silvia Novello, MD, PhD
Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy

Silvia Novello, MD, PhD, is Full Professor of Medical Oncology in the Oncology Department at San Luigi Hospital in Orbassano, Italy, part of the University of Turin. She is Head of the Thoracic Oncology Unit at the San Luigi Hospital, Orbassano (Turin), where she also tutors medical students and postgraduate students in Respiratory Medicine and Medical Oncology.

Prof. Novello’s research interests include thoracic malignancies, primary prevention, gender differences in lung cancer, basic, translational and clinical applied research on lung cancer, including pharmacogenomics. She is involved as PI in many International and national controlled clinical trials evaluating new approaches in diagnosis and lung cancer therapy.

From July 2012 until 2016, Prof Novello has been a Member of the Board of Directors of the International Association for the Study of Lung Cancer and since October 2016 Member of the Board of Directors of the Italian Association of Medical Oncology, Secretary of the EORTC Lung Cancer Group and member of several scientific societies including the American Society of Clinical Oncology, American Thoracic Society and the European Society of Medical Oncology.Currently, she the President of WALCE (Women Against Lung Cancer in Europe), a non profit European Association founded in 2006 in Turin, Italy, part of the scientific Committee of LuCe (Lung cancer Europe) and also member of the Scientific Committee of Bonnie J Addario Lung Cancer Foundation and Member of the Scientific Committee of ICAPEM (Investigación sobre Cáncer de Pulmón en Mujeres). She is the author or co-author of over 150 publications in peer-reviewed journals.

Dr. Shiono graduated from Yamagata University School of Medicine in 1992. He received his PhD from the Department of Hygiene and Preventive Medicine from the Yamagata University School of Medicine. Following his fellowship in Thoracic Surgery at Yamagata University Hospital, he became Chief of Thoracic Surgery at Yamagata Prefectural Nihonkai Hospital in 2001. From 2002 to 2004, he worked as a resident of the Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba. Currently, he is the Chief of the Department of Thoracic Surgery, Yamagata Prefectural Central Hospital. Dr. Shiono’s medical interests includes multi-disciplinary treatment for lung cancer, sublobar resection for lung cancer, surgical pathology, perioperative management, and pulmonary metastasis.

Francesco Passiglia, MD
Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy

Francesco Passiglia, MD, is Assistant Professor of Medical Oncology at University of Turin, Italy. Currently, he is consultant at the Thoracic Oncology Unit of San Luigi Hospital, Orbassano (Turin), where he is daily dedicated to the diagnosis and treatment of patients with thoracic malignancies. He is involved as PI or SI in many international and national clinical trials as well as translational research project mostly focusing on non-small cell lung cancer. Since October 2019 he is the scientific secretary of the Italian Association of Medical Oncology (AIOM) Lung Cancer Clinical Practice Guidelines. He is member of international scientific societies including the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the International Association for the Study of Lung Cancer (IASLC). He is the author or co-author of over 50 publications in peer-reviewed journals.

Focused issue outline:

  1. Editorial
  2. Kinase Fusion Molecular Pathways and Diagnostic Approaches
  3. Integrating Targeted Therapies in the Early Stage Strategies (adjuvant/neoadjuvant)
  4. How selecting best upfront therapy for metastatic disease? Focus on ALK
  5. How selecting best upfront therapy for metastatic disease? Focus on ROS1
  6. How selecting best upfront therapy for metastatic disease? Focus on RET
  7. How selecting best upfront therapy for metastatic disease? Focus on NTRK
  8. Targeting Oncogenic Fusions in Developing Countries: Challenges and Opportunities
  9. Mechanisms of Innate and Acquired Resistance to TKIs
  10. Overcoming Resistance: New generation inhibitors and rationale for combination strategies
  11. The role of IO in fusion-driven NSCLC
  12. Liquid biopsy for fusions detection
  13. Brain metastasis and Oligoprogression during TKI: how to treat and when?
  14. Emerging oncogenic fusions (NRG1, BRAF, MET, …) and the role of fusions as resistance mechanism to targeted therapy
  15. Future perspectives from pre-clinical models: new treatments are coming?